Skip Navigation LinksOA_ADAP_MM_2022_20_Replacement_of_Menactra_with_Menquadfi_Meningococcal_Conjugate_Vaccine

State of Cal Logo
EDMUND G. BROWN JR.
Governor

State of California—Health and Human Services Agency
California Department of Public Health


ADAP MM 2022-20
November 17, 2022


TO:
ADAP & PrEP-AP Enrollment Workers

SUBJECT:
Replacement of Menactra with Menquadfi Meningococcal Conjugate Vaccine on the ADAP & PrEP-AP Formulary

​ADAP MM 2022-20: Replacement of Menactra with Menquadfi Meningococcal Conjugate Vaccine on the ADAP & PrEP-AP Formulary


Effective September 26, 2022, Menactra was removed from the ADAP and PrEP‑AP formularies and replaced with MenQuadfi Meningococcal Conjugate Vaccine. The manufacturer Sanofi Pasteur transitioned to MenQuadfi as their sole Meningococcal Conjugate Vaccine in 2022. MenQuadfi is conjugate vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Sanofi Pasteur distributed a provider communication (PDF) that discusses this transition.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP and PrEP-AP drug formularies have been updated to reflect the addition of MenQuadfi.

If you have any questions regarding this update to the ADAP and PrEP-AP formularies, please contact the OA Formulary Specialist, James Vo at James.Vo@cdph.ca.gov.

Sharisse Kemp E Signature

Thank you,

Sharisse Kemp, MSW

ADAP Branch Chief

California Department of Public Health


Page Last Updated :